201 related articles for article (PubMed ID: 19447902)
1. The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.
Zhang S; Lei P; Liu X; Li X; Walker K; Kotha L; Rowlands C; Safe S
Endocr Relat Cancer; 2009 Sep; 16(3):835-44. PubMed ID: 19447902
[TBL] [Abstract][Full Text] [Related]
2. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.
Zhang S; Kim K; Jin UH; Pfent C; Cao H; Amendt B; Liu X; Wilson-Robles H; Safe S
Mol Cancer Ther; 2012 Jan; 11(1):108-18. PubMed ID: 22034498
[TBL] [Abstract][Full Text] [Related]
3. Lack of antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin's (TCDDs) induction of cytochrome P4501A1 (CYP1A1) by the putative selective aryl hydrocarbon receptor modulator 6-alkyl-1,3,8-trichlorodibenzofuran (6-MCDF) in the mouse hepatoma cell line Hepa-1c1c7.
Fretland AJ; Safe S; Hankinson O
Chem Biol Interact; 2004 Nov; 150(2):161-70. PubMed ID: 15535986
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha.
Pearce ST; Liu H; Radhakrishnan I; Abdelrahim M; Safe S; Jordan VC
Cancer Res; 2004 Apr; 64(8):2889-97. PubMed ID: 15087408
[TBL] [Abstract][Full Text] [Related]
5. Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.
Jin UH; Lee SO; Safe S
J Pharmacol Exp Ther; 2012 Nov; 343(2):333-41. PubMed ID: 22879383
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells.
Wormke M; Castro-Rivera E; Chen I; Safe S
J Steroid Biochem Mol Biol; 2000 Apr; 72(5):197-207. PubMed ID: 10822009
[TBL] [Abstract][Full Text] [Related]
7. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status.
Angus WG; Larsen MC; Jefcoate CR
Carcinogenesis; 1999 Jun; 20(6):947-55. PubMed ID: 10357772
[TBL] [Abstract][Full Text] [Related]
8. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.
Morrow D; Qin C; Smith R; Safe S
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):27-36. PubMed ID: 15026081
[TBL] [Abstract][Full Text] [Related]
9. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells.
Döhr O; Vogel C; Abel J
Arch Biochem Biophys; 1995 Aug; 321(2):405-12. PubMed ID: 7646066
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells.
Spink DC; Spink BC; Cao JQ; DePasquale JA; Pentecost BT; Fasco MJ; Li Y; Sutter TR
Carcinogenesis; 1998 Feb; 19(2):291-8. PubMed ID: 9498279
[TBL] [Abstract][Full Text] [Related]
11. Possible aryl hydrocarbon receptor-independent pathway of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced antiproliferative response in human breast cancer cells.
Yoshioka H; Hiromori Y; Aoki A; Kimura T; Fujii-Kuriyama Y; Nagase H; Nakanishi T
Toxicol Lett; 2012 Jun; 211(3):257-65. PubMed ID: 22521833
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibition of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced activity by alpha-naphthoflavone and 6-methyl-1,3,8-trichlorodibenzofuran using an aryl hydrocarbon (Ah)-responsive construct.
Merchant M; Safe S
Biochem Pharmacol; 1995 Aug; 50(5):663-8. PubMed ID: 7669069
[TBL] [Abstract][Full Text] [Related]
13. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Alley MC; Hose C; Ciolino HP; Yeh GC; Trepel JB; Vistica DT; Sausville EA
Mol Cancer Ther; 2004 Jun; 3(6):715-25. PubMed ID: 15210858
[TBL] [Abstract][Full Text] [Related]
14. Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat.
Astroff B; Safe S
Toxicol Appl Pharmacol; 1988 Sep; 95(3):435-43. PubMed ID: 2847362
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of aryl hydrocarbon receptor antagonists: inhibition of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 gene expression.
Merchant M; Morrison V; Santostefano M; Safe S
Arch Biochem Biophys; 1992 Nov; 298(2):389-94. PubMed ID: 1329656
[TBL] [Abstract][Full Text] [Related]
16. A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor.
Fukasawa K; Kagaya S; Maruyama S; Kuroiwa S; Masuda K; Kameyama Y; Satoh Y; Akatsu Y; Tomura A; Nishikawa K; Horie S; Ichikawa Y
Mol Cancer Ther; 2015 Feb; 14(2):343-54. PubMed ID: 25522763
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibition of MDA-MB-468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Wang WL; Porter W; Burghardt R; Safe SH
Carcinogenesis; 1997 May; 18(5):925-33. PubMed ID: 9163677
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells.
Merchant M; Krishnan V; Safe S
Toxicol Appl Pharmacol; 1993 Jun; 120(2):179-85. PubMed ID: 8390116
[TBL] [Abstract][Full Text] [Related]
19. Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor.
Harris M; Piskorska-Pliszczynska J; Zacharewski T; Romkes M; Safe S
Cancer Res; 1989 Aug; 49(16):4531-5. PubMed ID: 2545344
[TBL] [Abstract][Full Text] [Related]
20. Partial antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzofuran: mechanistic studies.
Harris M; Zacharewski T; Astroff B; Safe S
Mol Pharmacol; 1989 May; 35(5):729-35. PubMed ID: 2542761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
